women looking into microscope

Heidi Hagen – Lykan Bioscience

cell decor 1
CTO Sonoma Biotherapeutics

Heidi Hagen, MBA

Heidi Hagen has extensive experience in operations management and commercializing innovative technologies from her 30 years in the Biotech industry which includes 20 years in the Cell and Gene Therapy industry.



Currently, Heidi is Chief Technology Officer of Sonoma Biotherapeutics, a privately held company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. She also serves on the Board of Directors for a public, cell therapy commercial company, Vericel Inc. Previously she served on the board at Ziopharm Oncology Inc. (now called Alaunos Inc.), and as interim CEO, a publicly traded company developing immune-oncology gene and cell therapies. Prior to Ziopharm she was a co-founder of Vineti, a software platform company for cell and gene therapy supply chain management and served as Global COO for SOTIO Biotech a.s.. As the Senior Vice President of Operations for Dendreon for 10 years and she was responsible for the buildout of the operations for the first Active Cellular Immunotherapy (ACI), Provenge. She began her career at Immunex Corporation over ten years in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an M.S. in Bioengineering, and an MBA from the University of Washington.

Meet Lykan’s Scientific Advisory Board